Journal article
Discontinuation of benralizumab in Canadian patients with severe eosinophilic asthma
Abstract
Within 1 year, 15% of Canadian patients with severe asthma discontinue benralizumab. The reasons for discontinuation are not yet characterised. https://bit.ly/3kaRDlp.
Authors
Noorduyn SG; Johnston K; Osenenko K; Sriskandarajah N; Gendron A; Mbuagbaw L
Journal
ERJ Open Research, Vol. 7, No. 4, pp. 00465–02021
Publisher
European Respiratory Society (ERS)
Publication Date
October 2021
DOI
10.1183/23120541.00465-2021
ISSN
2312-0541